Joyce F Liu, Stéphanie Gaillard, Andrea E Wahner Hendrickson, Oladapo Yeku, Elisabeth Diver, Camille Gunderson Jackson, Rebecca Arend, Elena Ratner, Vivek Samnotra, Divya Gupta, Jon Chung, Hailei Zhang, Natalie Compton, Amanda Baines, Emeline Bacqué, Xiaohong Liu, Brunella Felicetti, Gottfried E Konecny
PURPOSE: To report the results of OPAL (ClinicalTrials.gov identifier: NCT03574779) cohort A, a single-arm substudy of niraparib plus dostarlimab and bevacizumab for the treatment of advanced, platinum-resistant ovarian cancer (PROC). METHODS: Participants with PROC who received 1-2 previous lines of therapy were treated with niraparib (200 or 300 mg once daily), dostarlimab (500 mg once every 3 weeks for four 21-day cycles, followed by 1,000 mg once every 6 weeks), and bevacizumab (15 mg/kg once every 3 weeks)...
May 2024: JCO Precision Oncology